Legal Concerns Loom Over Aquestive Therapeutics After Major Stock Drop Amid Securities Fraud Claims

Institutional investors involved with Aquestive Therapeutics, Inc. (NASDAQ: AQST) are facing some tough decisions as they evaluate their options following a significant decline in stock value. The company has come under scrutiny due to allegations of securities fraud, which have led to a loss of over 37% in stock price on a single day this past January. Those holding shares during the period from June 16, 2025, to January 8, 2026, may now consider the opportunity to act as lead plaintiffs in a forthcoming class action lawsuit.

On January 9, 2026, AQST shares plummeted by $2.30 per share, leaving many investors concerned about their holdings. As a direct result of this decline, institutional investors are encouraged to assess whether their interests were negatively impacted by the supposed inflation of stock values through misleading statements disseminated by the company’s management regarding regulatory timelines for its sublingual film epinephrine product, Anaphylm.

The United States District Court for the District of New Jersey is the arena where the lawsuit has been filed, bringing to light claims that the management's reassurances about Anaphylm gaining regulatory approval were not only overly optimistic but potentially deceptive. According to the allegations, the assertions made by the company did not accurately reflect the actual regulatory risks associated with the approval process, resulting in inflated share prices.

Joseph E. Levi, an attorney involved in the case, highlighted the important role institutional investors play in such legal actions. He emphasized that their involvement is crucial for ensuring that all shareholders' interests are adequately represented and corporate accountability is upheld. For institutional investors considering their next steps, it's essential to be aware of several factors, including fiduciary representation and the criteria for selecting lead plaintiffs under the Private Securities Litigation Reform Act.

Fiduciary Obligations and Opportunities

For those contemplating leading this class action, the process entails several obligations. Lead plaintiffs represent the class as a whole, directing litigation and negotiating recoveries on behalf of all affected investors. Being a lead plaintiff carries no personal financial risk, as any attorney fees will only be deducted from recoveries achieved for the class. This means that acting as a lead plaintiff can provide institutional investors a way to influence the direction of the case while minimizing their financial exposure.

Investors with significant holdings in AQST—especially those within retirement accounts, endowments, or pension plans—may face additional responsibilities to evaluate recovery options for their beneficiaries. It's crucial for these fiduciaries to consider the impact that the alleged securities fraud has had on their portfolios, particularly in light of a market correction that resulted from public revelations about deficiencies in the company’s New Drug Application (NDA).

When the FDA announced potential issues with the NDA for Anaphylm, market conditions shifted dramatically, leaving investors scrambling to reassess their strategies.

Next Steps for Institutional Investors

The timeline for filing as lead plaintiffs isn't long. The court has set a deadline for May 4, 2026, creating a pressing need for institutional investors to evaluate their positions. Those unwilling to assume lead plaintiff status still maintain their rights as part of the class and can participate in any future settlements that arise from the action.

As with any securities case, the existence of a well-articulated strategy is essential. Selecting and retaining legal counsel who understands the intricacies of the litigation process can significantly influence the outcome. Institutional investors are urged to consult with legal experts to better understand their options and the implications of their decisions moving forward.

In summary, the case against Aquestive Therapeutics highlights the complexities and potential perils of investing in a landscape where regulatory risks are not always clear. This serves as a prompt to all investors about the importance of due diligence and the need for transparency from companies regarding their regulatory processes. As the situation continues to evolve, investment communities are closely monitoring the developments, eager to uncover the truth behind the unfortunate circumstances surrounding AQST shares.